Weekly Review of Healthcare Industry Investments (20250714): Innovations in NK Cell Therapy, Women's Health Diagnostics, and AI-Driven Medical Solutions

【NK Cell Therapy】Shanghai Enke Cell Technology Co., Ltd. is a biotechnology company focusing on the development of innovative NK cell therapy technologies. Based on over 30 years of research by the team into the fundamental biology, preclinical, and clinical translational exploration of NK cells, with the aim of solving major clinical disease treatment challenges (cancer, autoimmune diseases, aging and degenerative diseases, immunodeficiency and related diseases, etc.), it is committed to becoming a world-leading cell therapy company with deep expertise in NK cell therapy and cutting-edge technologies. The company owns a unique allogeneic peripheral blood NK cell expansion and cryopreservation platform capable of producing “off-the-shelf” clinical-grade products through its ABCDE-NK® industrial production platform (a single blood donation can yield trillions of NK cells). Relying on target discovery technology based on NK cell-specific tumor recognition receptors/ligands (NKR-NK™), and using synthetic immunology platform technologies such as logic gate genetic circuits (SynNK™), the company achieves multipotent, intelligent, and controllable gene editing of NK cells, enabling them to precisely target cancer cells, adapt to the tumor microenvironment, and accurately match donor and recipient effector/target cells. In 2024, two of the company’s NK cell products received clinical trial approvals from the FDA and CDE, respectively.

【Investors】Pudong Venture Capital, CAS Advanced Industry Fund

【Gastrointestinal Endoscopy】Cosmind was founded on September 9, 2022, with its headquarters located in Longhua District, Shenzhen. The company focuses on the research, development, and production of flexible electronic endoscopes for gastroenterology. Cosmind has gathered a group of industry veterans with years of experience in the endoscope field, accumulating extensive hands-on expertise in product development, manufacturing processes, and commercialization. Its AI+V1000 system+optical magnification endoscope full-link solution features the "world’s first" one-touch autofocus function, greatly improving diagnostic and treatment efficiency. Additionally, the V1000 system offers multiple optical imaging modes that comprehensively cover all clinical scenarios from screening to diagnosis and treatment. The company independently developed China’s first integrated flexible endoscopy platform, along with innovative gastroscope and colonoscope products. It has also introduced several revolutionary products around this platform, covering clinical fields such as gastroenterology, respiratory, ENT, gynecology, and urology. Cosmind adheres to market promotion methods centered on professional medical education. Since its establishment, the company has conducted nearly 200 academic activities and hands-on teaching sessions. Its innovative "China’s first" integrated flexible endoscopy technology platform has been implemented in nearly a thousand hospitals across China, including top-tier tertiary teaching hospitals as well as various levels of hospitals in county-level markets. At the same time, the company is actively expanding into overseas markets and has formed strategic partnerships with numerous leading commercial partners.

【Investors】Yahui Investment, IDG Capital, Tencent

【Invisible Aligner】Hangzhou Shuyaqi Medical Technology Co., Ltd. is an emerging medical device enterprise focusing on the field of orthodontics, established on April 30, 2025. It belongs to the "Shuya Galaxy" brand matrix under Hansfu (Hangzhou) Medical Technology Co., Ltd. With the core strategy of "cost-effective products + digital services," the company focuses on the invisible orthodontics market and quickly becomes a potential brand in China-produced invisible orthodontic solutions through technological innovation and strategic synergy. In July 2025, Shuyaqi received strategic investment from the leading Chinese invisible orthodontics company, Times Angel Group (holding 35%), and collaborates with its parent company Hansfu (holding 65%) to explore a full-ecosystem orthodontic solution integrating "equipment + materials + software," accelerating the accessibility process in emerging markets. The company’s core product is invisible aligners, covering two main series: Classic Edition and Starry Sky Edition. Relying on the parent company Hansfu’s complete dental product portfolio (including fixed orthodontics, self-ligating brackets, early intervention products for children, intraoral scanners, 3D printers, and other digital equipment), it provides a "one-stop customized dental product solution."

【Investors】Angelalign

【Female Health In Vitro Diagnostics】Shuwen Biotech is an international company specializing in the development, production, sales of in vitro diagnostic reagents for women's health and medical testing services. It has successively signed exclusive cooperation agreements with many well-known universities, enterprises, and research institutions at home and abroad, including Yale University, the University of Chicago, the Max Planck Institute, the University of Cologne, Fudan University Cancer Hospital, BioNTech, Myriad Genetics, etc. By combining independent innovation, the company has obtained more than 100 exclusive diagnostic patents and successfully developed multiple first-in-class diagnostic new products and services. In the field of maternal and child health, the company has launched Xiangongzhu®, the world’s first approved at-home self-test product for preeclampsia in pregnant women, and Wenxuan’an®, the world’s first rapid urine test product for preeclampsia in pregnant women. The at-home self-test product Xiangongzhu® is used for screening and diagnosing preeclampsia after 20 weeks of pregnancy, allowing pregnant women to operate it at home and independently read the results within 5-10 minutes. This makes preeclampsia testing unrestricted by time and location, enabling pregnant women to test at home between two hospital prenatal check-ups, helping doctors and pregnant women detect preeclampsia early and intervene promptly to avoid serious consequences. In the field of breast cancer, the company has created a series of more than ten detection products covering the entire course of breast cancer, such as MamaTyper®, Wenfuxi®, Wenspute®, Wenru® series, and maxBRCA, providing one-stop solutions for precision medicine, companion diagnostics, prognosis, recurrence monitoring, and other stages of breast cancer. Regarding globalization market layout, the company leverages the market channels and promotion capabilities of multinational companies, cooperating with industry giants like Sysmex and other distributors to promote EU-certified products in nearly 50 countries worldwide. The company has established professional market promotion teams and channels domestically and internationally, establishing its brand status in the industry. In Europe, through its wholly-owned subsidiary in Germany, Seroclin Biotech, it promotes first-in-class products; the molecular subtyping product for breast cancer, MammaTyper®, has been included in Spain's breast cancer diagnosis and treatment guidelines. In Burkina Faso, Africa, MammaTyper® has been advocated by the country's president for nationwide precision diagnosis and treatment of breast cancer patients. Domestically, MammaTyper® has also been recommended by the guidelines of the Chinese Anti-Cancer Association and has entered numerous provincial tumor hospitals.

【Investors】Yuansheng Ventures, Jinchuang Ventures

【Intelligent Diagnosis Platform】Hangzhou Quanzhen Medical Technology Co., Ltd. is a company specializing in medical artificial intelligence products and information technology services. The company has been awarded by the National Health Commission of China for several consecutive years. Its independently developed Quanzhen medical large model and AI products have been successfully applied in many well-known hospitals in China, such as Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine, Zhejiang Provincial People's Hospital, Zhejiang Hospital, the Fourth Affiliated Hospital of Zhejiang University, and Beijing Dongzhimen Hospital. At the grassroots level, the company has served 105 district and county health bureaus and 15,000 medical institutions within their jurisdiction. The company’s AI doctor assistant product, based on a large language model, is the first medical artificial intelligence product of its kind in China and the only intelligent doctor assistant to be fully deployed across dozens of large comprehensive tertiary hospitals in China. Using natural language processing, image recognition, speech recognition, and large model technology, the product can guide and pre-diagnose patients through AI dialogue before consultations, assist doctors in automatically generating medical records during consultations, analyze patient symptoms and medical history, and provide intelligent diagnostic suggestions to reduce the risk of missed and misdiagnosis, improving diagnostic accuracy and efficiency. After consultations, the AI assistant can automate tedious tasks such as patient follow-ups, reducing the workload of doctors and enhancing work efficiency and medical service quality. The product also provides personalized medical service recommendations based on individual patient differences and needs, significantly improving the patient experience and quickly increasing patient trust and satisfaction with the hospital.

【Investors】Sichuan Canon Investment Co., Ltd.

【Home-based Elderly Care Services】Pastoral Home Senior Care Group, founded in December 2015, is a comprehensive service provider specializing in home-based elderly care services and is a pioneer in Beijing's home-based elderly care market. With the mission of "ensuring that everyone has support in old age without leaving home; addressing the urgent needs of the elderly and resolving their difficulties; fulfilling filial piety on behalf of children worldwide and alleviating burdens for families and society," the group has pioneered an integrated online + offline smart home-based elderly care model (home-based elderly care services + industry support + AI intelligent systems). The group has established its own service teams and systems to provide 24/7 dedicated community presence, 24-hour emergency rescue reaching households within 15 minutes, and one-stop comprehensive services. It operates 30 service stations, 1 senior care station, 1 senior club, and 1 suburban residence base. Services include emergency rescue, hospital registration and medicine collection, medical accompaniment, nanny and hourly worker services, haircuts and foot care, cleaning and maintenance, supermarket shopping assistance, transportation services, home safety inspections, age-friendly renovations, property management, travel and residence services, end-of-life care, legal assistance, and more. Upstream, it drives an ecosystem including smart homes, smart communities, age-friendly modifications, intelligent elderly care equipment, community diagnostic devices, home diagnostic products, and AI medical services, making it a leading brand in China’s trillion-yuan elderly care market.

【Investors】Yuefeng Capital, Jinsha River United Capital, Fanzhi Cloud Chain